Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 15, 04 December 2023
Open
Access | Article
Vaccine development against Helicobacter pylori
* Author to whom correspondence should be addressed.
Abstract
Helicobacter pylori (Hp) colonizes and persists in the gastric mucosa. It was the Class I carcinogenic factor, and the International Agency for Research on Cancer attributed 92% of stomach cancers to Hp, and according to data, nearly 50% of people in China are infected with Helicobacter pylori. At present, antibiotics are mainly used in clinical treatment, but with the increase of Hp resistance, antibiotics will lose their effect. The development of Hp vaccine has become a new way to prevent and control Hp infection. Components such as flagella, urease, virulence factors and outer membrane proteins involved in the process of Hp infection, colonization and reproduction, and have also become candidate antigens in the development of Hp vaccine. Specifically, study have suggested that flagellin vaccine can decrease infection rate. In the meantime, recombinant Hp antigens and dmLT were efficient for protection from the Hp infection. This article summarizes the progress of Hp vaccine research and development, hoping to provide reference for related research.
Keywords
Helicobacter Pylori, Vaccine, MV-Hspa, Bacterial Outer Membrane Vesicles (OMV)
References
1. Khim K, et al. Deimmunization of flagellin for repeated administration as a vaccine adjuvant. NPJ Vaccines. 2021 Sep 13;6(1):116.
2. Cui B, et al. Flagellin as a vaccine adjuvant. Expert Rev Vaccines. 2018 Apr;17(4):335-349.
3. Mori J, et al. Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori. Vaccine. 2012 Aug 31;30(40):5856-63.
4. Liu G, et al., Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One. 2011;6(6):e20928.
5. Farshidi N, et al. Preparation and pre-clinical evaluation of flagellin-adjuvanted NOM vaccine candidate formulated with Spike protein against SARS-CoV-2 in mouse model. Microb Pathog. 2022 Oct;171:105736.
6. Zhong, Youxiu et al. Oral immunization of BALB/c mice with recombinant Helicobacter pylori antigens and double mutant heat-labile toxin (dmLT) induces prophylactic protective immunity against H. pylori infection. Microbial pathogenesis vol. 145 (2020): 104229.
7. Sjökvist O.L., et al. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infection and immunity vol. 81,5 (2013): 1532-40.
8. ZHAO Cui, Zhao Fuguang, Huang Ya. Research progress of candidate vaccine antigens of Helicobacter pylori [J]. Chinese Journal of Immunology, 2018, 34(06):957-961.
9. Zhou Duo, Zhao Zhengyan. Research progress of anti-tumor effect of measles virus [J]. Journal of Zhejiang University (Med Edition),2015,44(04):458-464.
10. Xueqing G., et al. Gene cloning and sequence analysis of heat shock protein A subunit of human Helicobacter pylori [J]. Chinese Journal of Digestion,2001(01):48-49.
11. Tomb JF. et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature, 1997, 388.539-547.
12. Iankov I D , et al.Live Attenuated Measles Virus Vaccine Expressing Helicobacterpylori Heat Shock Protein A[J].Molecular Therapy — Oncolytics, 2020, 19:136-148.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-193-3
- ISBN (Online)
- 978-1-83558-194-0
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/15/20240458
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited